Clinical Spectrum, Treatment, and Outcome of Patients with Type II Mixed Cryoglobulinemia without Evidence of Hepatitis C Infection
- 15 January 2011
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 38 (4), 716-722
- https://doi.org/10.3899/jrheum.100898
Abstract
Objective. The clinical spectrum, etiologies, and best therapeutic approaches of type II mixed cryoglobulinemia (MC) not associated with hepatitis C virus (HCV) infection have been poorly described to date. We studied the clinical presentation and outcome of patients with type II MC with no evidence of HCV. Methods. This was a multicenter retrospective study on the clinical presentation and outcome of patients with type II MC without evidence of HCV infection. Only patients with symptomatic MC were included. Results. Thirty-three patients were included (median followup 67.2 mo). Extensive investigations for associated diseases were performed at presentation. MC was related to an autoimmune disease in 14 patients, to a lymphoid malignancy in 4 patients, and to an infectious disease in 2 patients, while MC was classified as essential (primary) in 13. Essential MC tended to be more severe than secondary disease with, in particular, more frequent renal and peripheral nerve involvement. Most patients were treated with steroid with or without immunosuppressive agents, mainly cyclophosphamide. These treatments were unable to induce sustained remission. One patient was successfully treated with lenalidomide. Seven patients with nonmalignant MC were treated with rituximab; 2 had a sustained complete remission, 3 improved greatly but relapsed within 5 months, and 2 experienced a disease flare. Conclusion. An important proportion of non HCV-related type II MC remains essential. Efforts should be made to find other etiologies than HCV, because treatments with steroid and immunosuppressants are not satisfactory, especially in severe forms. In these situations anti-CD20 therapy may present the best option but should be used with caution. New agents such as lenalidomide remain to be evaluated.Keywords
This publication has 24 references indexed in Scilit:
- Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: Data from the French Autoimmunity and Rituximab registryArthritis Care & Research, 2010
- Lenalidomide in multiple myeloma: current role and future directionsExpert Opinion on Pharmacotherapy, 2010
- Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?Annals Of The Rheumatic Diseases, 2007
- CryoglobulinemiaBlood Reviews, 2007
- Type II Cryoglobulinemia Is Not Associated with Hepatitis C InfectionAnnals of the New York Academy of Sciences, 2007
- Lack of efficacy of Rituximab in a patient with essential mixed cryoglobulinaemiaRheumatology, 2006
- Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroidsRheumatology, 2006
- Efficacy and safety of rituximab in type II mixed cryoglobulinemiaBlood, 2003
- Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20Blood, 2003
- CryoglobulinemiaMedicine, 2001